Natural immunosuppressive agent, effectively blocking T cell proliferation and survival while profoundly inhibiting pro-inflammatory IFNγ and IL-17 production by fully differentiated effector Th1 and Th17 cells, also acting as an estrogen receptor antagon

Fluorescent substrate which can be hydrolyzed by the proteasome to release free AMC and the fluorescence of which is proportional to the proteasome activity

Novel antagonist of G-protein-coupled receptor SUCNR1 (succinate receptor 1 or GPR91)

Novel potent inhibitor of osteoclastogenesis, suppressing both equilibrative nucleoside transporters and concentrative nucleoside transporters

Novel inhibitor of airway inflammation and hyperresponsiveness in experimental models of chronic obstructive pulmonary disease (COPD)

Antibacterial, inhibiting bacterial folic acid synthesis by competing with para amino benzoic acid

β-Lactam antibiotic against multi-drug resistant pathogens

Novel inhibitor of RhoG-hepcidin uptake

Neuroprotective agent, alleviating stroke-induced neuroinflammation

Peripheral vasodilator

Novel, potent, selective, and competitive antagonist of LTD4 and LTE4

D2 selective dopamine agonist, showing anxiolytic and anti-parkinsonian activities

Novel fibroblast growth factor receptor modulator for treating neurodegenerative diseases

5-HT2 antagonist

Potent Inhibitor of Plasmodium FK506 Binding Protein 35 (FKBD35), also act as a HIV inhibitor

Antagonist of the mammalian bile acid sensor farnesoid-X-receptor (FXR)

Selective D2 dopamine receptor antagonist

D2 dopamine receptor partial agonist in adenylyl cyclase inhibition assay and antagonist in the GIRK and phospho ERK1/2 assays

Novel clickable tumor-specific irreversible inhibitor of stearoyl CoA desaturase (SCD)

Natural potent alpha-mannosidase inhibitor, exhibiting antimetastatic, antiproliferative, and immunomodulatory activities

Potent differentiating agent

Novel selective OXE receptor antagonist

Novel highly potent and selective CDK7 inhibitor, demonstrating broad anti-tumor activity in vivo

Novel universal opioid receptor agonist

Novel inhibitor of the Syk kinase (spleen tyrosine kinase)

Novel potent and specific inhibitor of syncytin-mediated cell fusion, completely blocking cell fusion at 1.6 μg/ml

Negative control of Syn-1 peptide, having the same amino acid composition as Syn-1 peptide, but a scrambled sequence

Novel Mycobacterium tuberculosis growth inhibitor

Novel microtubule-stablizer

K+ channel blocker

Novel TLR7 agonist via immune response induction and tumor microenvironment modulation

Potent inhibitor of both rodent and human MAO-B, proved to be safe in high doses with no hERG and mutagenic activities and demonstrated neuroprotection in an in vivo chronic model of PD

Novel COX-2 inhibitor

Potent and selective CCKA receptor antagonist

Novel potent PPARγ antagonist with much improved drug-like properties and promising pharmacokinetic profile

Selective class B inhibitor of the Ca -activated Cl- Channel, Ano1(TMEM16A)

Selective class D inhibitor of the Ca -activated Cl- Channel, Ano1(TMEM16A)

Type-A trichothecene mycotoxin

Novel inhibitor of the type III secretion system (T3SS), acting as a anti-microbial agent against Xanthomonas oryzae pv. oryzae (Xoo)

Novel Inhibitor of Adenovirus Gene Transfer

Novel Inhibitor of Adenovirus Gene Transfer

Inhibitor of HIV-1 Assembly that Targets the Phosphatidylinositol (4,5)-bisphosphate Binding Site of the HIV-1 Matrix Protein

Novel inhibitor of the catalytic functions of peroxiredoxin (Prx) and thioredoxin (Trx) systems

Natural radical scavenger on ABTS

Novel Inhibitor of Parasite Motility and Invasion

Novel Inhibitor of Parasite Motility and Invasion

Novel Irriversible Inhibitor of Parasite Motility and Invasion

Novel Potent Dual AChE/GSK-3 Inhibitor for the Treatment of Alzheimers Disease

Novel potent p53-MDM2/X antagonist, inhibiting MDM2 potently with a Ki value of 58 nmol/L, inducing accumulation of p53, p21 and MDM2, inhibiting cell cycle progression of U-2 OS cells at G1 phase in a p53-dependent manner

Novel inhibitor of the Klebsiella pneumoniae VapBC toxin-antitoxin (TA) system, acting as antimicrobial agents by disrupting the VapBC complex and activating VapC

Novel AMPA receptor potentiator with little agonistic effect, producing antidepressant-like effect without causing psychotomimetic effects

Long-lasting ergosterol biosynthesis inhibitor

Potent FAAH Inhibitor

Novel anti-HIV CCR5 antagonist

Novel selective 5-hydroxytryptamine type 2C (5-HT2C) receptor agonist

Novel inhibitor of the epigenetic modulator lysine-specific demethylase 1A (LSD1)

Natural ferroptosis inducer, killing colorectal cancer cells in vitro and in vivo

CYP26 inhibitor, potentiating the effects of all-trans retinoic acid on cultured human epidermal keratinocytes

Natural neurotrophic agent, promoting neurite outgrowth from neurons through PI3K/Akt pathway

Novel Antibody-Drug Conjugate PBD Dimer Payload

Superagonist at the human thyrotropin-releasing hormone receptor, reversing opioid-induced respiratory depression in isoflurane anesthetized rats

Novel Fluorescent dATP for DNA Synthesis In Vivo, exhibited high brightness, low toxicity, and rapid incorporation and depletion kinetics in both a vertebrate (zebrafish) and a nematode (Caenorhabditis elegans)

Potent and selective non-peptide δ1 opioid receptor agonist

Novel angiogenesis stimulator, promoting multiple key steps of angiogenesis parially via Akt and MAPK signalling pathways, showing anti-ischemic and anti-atherosclerosis activities, also acting as a putative PPARγ agonist

Novel potent Na V -targeting peptide, exhibiting significant increased potency for Na V 1.1, Na V 1.2, Na V 1.3, Na V 1.6 and Na V 1.7 involved in several neurological disorders including acute and chronic pain, motor neuron disease and epilepsy

Novel potent Na V -targeting peptide, exhibiting significant increased potency for Na V 1.1, Na V 1.2, Na V 1.3, Na V 1.6 and Na V 1.7 involved in several neurological disorders including acute and chronic pain, motor neuron disease and epilepsy

ADAM-17 (TACE) and MMP inhibitor, sensitizing cancer stem cells to the lethal effects of 5-FU and blocking shedding of TNF-α from cell membranes

Potent P-glycoprotein (P-gp) inhibitor

Novel selective norepinephrine reuptake inhibitor, displaying significant norepinephrine transporter (NET) inhibitory activity toward the serotonin or dopamine transporters

Tubulin-binding dolastatin-15 analog, demostrating a wide spectrum of In Vivo antitumor activity

Potent and orally active V 1B receptor antagonist with antidepressant and anxiolytic activities in rodents

Potent and selective sphingosine 1-phosphate 1 (S1P1) receptor antagonist (IC50 = 7.8 nM)

Novel potent, selective, and orally active CRTH2 antagonist

Trans-activator of transcription (TAT) peptide, increasing Hepta-histidine (7H) permeability into cells for treatment of iPS cell-derived neurons carrying Tau or APP mutations suppressed Tau phosphorylation

Novel brain penetrant Cx43 hemichannel blocker

Potential neuroprotective agent, showing effects on cellular models of oxidative stress and neuroinflammation

Selective mast-cell-stabilizing agent, inhibiting ozone-induced airway hyperresponsiveness

Novel antagonist of IL-6 signaling

Novel antibiotic against Mycobacterium tuberculosis (Mtb), potently killing replicating, virulent Mtb H37Rv in a clavulanate-dependent manner

Novel potent MCT1 inhibitor, exhibiting good single agent anticancer efficacy properties

Highly potent activator of Nrf2; Potent phase 2 cytoprotective pathway inducer and liver carcinogenesis blocker

Novel TBK1/IKKε inhibitor

Novel anti-angiogenesis and vascular disrupting agent, exhibiting moderate inhibitory cell proliferation activity

Novel anti-angiogenesis and vascular disrupting agent, exhibiting moderate inhibitory cell proliferation activity

Novel agonist for nicotinic acetylcholine receptors (nAChRs), modestly selectively targeting α6β2 subtype

Novel potent and selective ligand of Brd2(2)

Aquaporin 1 (AQP1) channel blocker

Potent CB1 receptor inverse agonist

Novel orally bioavailableγ-secretase modulator, reducing Aβ42 levels

FPR Agonist 43 (compound 43) is a dual formyl peptide receptor 1 (FPR1) and formyl peptide receptor 2 (FPR2)/ALX agonist.

Potent and selective antagonist of adenosine A2A receptors

Non-competitive modulator of the proteasome inducing apoptosis a panel of myeloma and leukemia cell lines

Novel TRPM8 channel blocker

Potent TRPM8 antagonist, exhibiting antiallodynic properties in pain models

Antimalarial; Novel inhibitor of HepG2

Novel Inhibitor of the malaria parasite protein kinase CLK3, inhibiting the development of liver-stage parasites, killing asexual blood-stage parasites at the trophozoite and schizont stages of the erythrocytic cycle, blocking the development of sexual ga

Highly potent NR2B-selective NMDA receptor antagonist

Nonpeptide partial agonist of oxytocin (OT) and vasopressin V2 receptors

Potent and selective polo-like kinase 2 (PLK2) inhibitor

Novel potent and selective CHK1 kinase inhibitor

Novel Integrin very late antigen-4 (VLA-4; α4β1) antagonist, blocking the activation of inflammatory cells.

Novel GPR35 agonist

Insulin receptor sensitizing agent; Selective inhibitor of protein-tyrosine phosphatase 1B (PTP1B)

Potent equilibrative nucleoside transporter 4 (ENT4) inhibitor

Sorafenib analogue, retaining cytotoxicity similar to sorafenib in various human cancer cell lines and strongly inhibiting growth in the NCI-60 cell line panel

Novel degrader of the anaplastic lymphoma kinase (ALK) fusion protein, effectively inducing ALK degradation and inhibiting the growth of ALK fusion positive cell lines, SU-DHL-1 and H3122, significantly reducing the tumor growth in H3122 xenograft model

Novel IKZF1/3 degrader, inhibiting the proliferation of multiple myeloma cells in vitro as well as in vivo

Novel selective opioid receptor antagonist at all three receptor types

Novel potent BET protein degrader, inhibiting cell proliferation due to suppressed C-MYC transcription

Novel long-acting β 2 -adrenoceptor agonist

Hepatotoxicity inducer, significantly up-regulating the expression of genes involved in endoplasmic reticulum stress and Toll-like receptor (TLR) pathway

Novel Specific Copper Chelator, Reducing Memory Impairments in Alzheimer's Disease Mouse Models

Novel potent inhibitor of tyrosyl-DNA phosphodiesterase 1 (Tdp1)

Novel inhibitor of the p53-Hdm2 protein-protein interaction, dose-dependently stabilized P53 and increased P21 and MDM2 expression in JAR choriocarcinoma cells, inducing the p53 regulated gene (PIG-3) and caspase activity

Novel antimalarial agent

Novel inhibitor of viral p37, blocking the ability of virus particles to be released from infected cells, being used for the treatment of smallpox, monkeypox, orthopoxvirus, and orthopoxviral Disease.

Novel monocyte/macrophage targeted histone deacetylase inhibitor

CCR2b receptor antagonist

Natural antibacterial agent, being active against gram-positive bacteria.

Potent and selective M1 antimuscarinic

Mucolitic agent, inhibiting activation of nuclear factor kappa-κB (NF-κB) by blocking phosphoinositide 3-kinase/protein kinase B (PI3K/Akt)/IκB kinase (IKK) activities, showing the anti-inflammatory properties on inflammation-associated skin diseases

Photosensitizing agent used in the treatment of squamous cell carcinoma of the head and neck, also showing activity agaimst COVID-19 Mpro

COX/5-LOX inhibitor and cytokine-modulating anti-inflammatory agent

Peptide vaccine, residues (611-626) of the human telomerase reverse transcriptase catalytic subunit (hTERT), for the treatment of solid cancers

Selective Thromboxane_receptor>thromboxane receptor antagonist

Mutually Orthogonal Bioorthogonal Amino Acid, Enabling Efficient Protein Dual-Labeling in Cells

Reversible inhibitor of vesicular monoamine transporter 2, showing anti-chorea effect and decreasing uptake of monamines into synaptic vesicles, as well as depletion of monoamine storage

Activator of the hepatic interferon pathway in rats

Potent inhibitor of protein synthesis, inhibiting translation by binding within the ribosomal exit tunnel

Inducer of S phase arrest and apoptosis in hepatocellular carcinoma QGY-7701

Antitubercular agent

Potent and selective human leukocyte 5-lipoxygenase (5-LOX) inhibitor

Novel endothelin (ET) receptor antagonist

Novel multipotent anti-Alzheimer agent, selectively inhibiting human butyrylcholinesterase (BChE), having strong antioxidant activity and good β-amyloid (Aβ) anti-aggregation properties

Novel GSK-3β inhibitor, showing anti-neuroinflammatory effects in lipopolysaccharide (LPS) activation of spontaneously immortalized SIM-A9 microglial cells and of mouse cortical microglia, inhibiting LPS-induced production of nitric oxide and the proinfla

Novel cell-active, selective class IIa HDAC inhibitor

CNS-penetrant selective class IIa histone deacetylase (HDAC) inhibitor, exploiting the >100-fold selectivity over class I/IIb HDACs

Cyclized tamoxifen analog, selective ER modulator (SERM)

Novel and Potent Stem Cell Mobilizer; Inhibitor of SDF-1α/CXCR4 binding

Novel potent SARS coronavirus (CoV) 3CL protease inhibitor (Ki = 53 nM)

Novel dual VEGFR/Src kinase inhibitor

Novel inhibitor of T315I mutant enzyme, exhibiting reasonable in vivo efficacy in a xenograft mouse model harboring T315I

Novel, Potent, Selective, Water Soluble, Brain-Permeable EP2 Receptor Antagonist

Novel inhibitor of mitochondrial calcium uptake (#333333; font-family: "Open Sans", HelveticaNeue, "Helvetica Neue", Helvetica, Arial, sans-serif; font-size: 15px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight:

Highly selective, potent, cell-permeable fluorescent irreversible tissue transglutaminase (TG2) inhibitor

EP2 allosteric potentiator

Potent and selective nociceptin opioid receptor (NOP) agonist

Potent and selective nociceptin opioid receptor (NOP) agonist

Potent and selective nociceptin opioid receptor (NOP) agonist

Potent and Selective Antagonist for Human EP2 Receptors

Novel potent and structure-specific inhibitor of pre-miR-200c, reversing a type 2 diabetes phenotype

Novel potent TGR5 agonist, displayind a significant glucose-lowering effect and stimulated GLP-1 and insulin secretion in TGR5H88Y mice but not in wild-type animals

Novel Potent Agonist of TGR5 Receptor

Cell-permeable, potent, and selective inhibitor of PI 3-K isoforms p110ß/p110d

Potent and selective inhibitor of PI 3-K

Novel highly potent and specific inhibitor of TLR8, targeting an unconventional pocket on the TLR8 protein-protein Interface

Natural potent human carboxylesterase 2 (hCES2) inhibitor (IC50: 5.05 μM)

Natural antibiotic, being active against P. aeruginosa both in vitro and in vivo.

Novel glutaminase activity inhibitor, showing a partial uncompetitive inhibition in vitro and a significant reduction of ammonia and glutamate production in vivo

Prodrug of Thiamphenicol, inhibiting the 50S subunit of the bacterial ribosome and protein translation

Novel antibiofilm agent, disturbing symbiotic balance between C. albicans and S. mutans in dual species biofilm

Highly efficient bioregulator of plant morphogenesis in the tissue culture technique, inducing diverse responses ranging from induction of callus to embryogenesis or organogenesis, acting through modulation of the endogenous plant growth regulators, modif

Novel protein-protein interaction inhibitor of PAC3 homodimer

Novel selective anticancer agent, selectively inducing cancer cell death in a caspase independent pathway

First-in-class potent, selective, reversible, and tight binding inhibitor of human monoamine oxidase B (hMAO-B) (hMAO-B IC 50 = 1.52 ± 0.15 nM)

Novel potent DENV2-NS2B/NS3pro inhibitor

Firefly luciferin analog as a key element of bioluminescent reporters for oxidation state and thiol/disulfide equilibria

GABAA receptor agonist

Novel Potent Inhibitor of the Opioid Receptors and the Ion Channels

Novel inducer of apoptotic cell death in platinum-resistant A2780cis human ovarian cancer cells, exhibitong a strong inhibitory effect in ovarian CSC-LCs in combination with cisplatin

Steroidomimetic and Chimeric Microtubule Disruptor

Selective Tau ligand, selectively binding to neurofibrillary tangles and neuropils in people with Alzheimer's disease

Novel orthosteric-allosteric dual inhibitor of PfHT1 as selective antimalarial agent

Novel orthosteric-allosteric dual inhibitor of PfHT1 as selective antimalarial agent

Novel orthosteric-allosteric dual inhibitor of PfHT1 as selective antimalarial agent

Novel potent, highly selective and orally available PI3Kδ inhibitor

Novel phosphodiesterase 10A (PDE10A) inhibitor for treatment of schizophrenia

Phosphodiesterase 10A (PDE10A) inhibitor

Novel dose-dependent inhibitor of HDAC1, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, and HDAC9; NOX Inhibitor

Novel selective thrombin inhibitor, inducing conformational allostery

Novel multivalent ligand that bridges the allosteric and orthosteric binding sites of the M2 muscarinic receptor

Anti-epileptic and anticonvulsant agent, acting as a selective GABA reuptake inhibitor

Anthraquinone-fused enediyne antitumor agent for development of antibody-drug conjugates (ADCs)

Muscarinic receptor antagonist, anticholinergic,and parasympatholytic

Natural anticancer agent fortreatment of mast cell tumor (MCT)

Widely used oxidation-reduction indicator

Macrolide antibiotic for the treatment of bovine respiratory disease and ovine respiratory disease associated with Mannheimia (Pasteurella) haemolytica

Antiviral, antineoplastic, and anti-inflammatory agent; Orally active interferon inducer, inhibiting Ebola virus (EBOV)

Novel pan-histone-deacetylase inhibitor with alkylating activity

Neurotoxin, acting via vanilloid receptors of sensory nerves

Novel hepcidin antagonist

hPPAR

Dual PPA

hPPAR-pan agonist

Anti-arrhythmia agent

Novel AC220-based FLT3 degrader

Novel AC220-based FLT3 degrader

The first small molecule degrader, inducing anaplastic lymphoma kinase (ALK) degradation, including in non-small-cell lung cancer (NSCLC), anaplastic large-cell lymphoma (ALCL), and neuroblastoma (NB) cell lines

The first small molecule degrader, inducing anaplastic lymphoma kinase (ALK) degradation, including in non-small-cell lung cancer (NSCLC), anaplastic large-cell lymphoma (ALCL), and neuroblastoma (NB) cell lines

Novel Insulin Receptor Modulator